These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12723560)

  • 1. EANM procedure guidelines for 32P therapy.
    EANM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP17-9. PubMed ID: 12723560
    [No Abstract]   [Full Text] [Related]  

  • 2. EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
    Tennvall J; Brans B
    Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1324-7. PubMed ID: 17396258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI
    Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EANM procedure guidelines for therapy with iodine-131.
    EANM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP27-31. PubMed ID: 12723563
    [No Abstract]   [Full Text] [Related]  

  • 5. EANM procedure guidelines for radiosynovectomy.
    Clunie G; Fischer M;
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP12-6. PubMed ID: 12723558
    [No Abstract]   [Full Text] [Related]  

  • 6. EANM procedure guidelines for treatment of refractory metastatic bone pain.
    Silberstein EB; Taylor AT;
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP7-11. PubMed ID: 12723557
    [No Abstract]   [Full Text] [Related]  

  • 7. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report.
    Murphy S; Rosenthal DS; Weinfeld A; Briere J; Faguet GB; Knospe WH; Landaw SA; Laszlo J; Pisciotta AV; Tartaglia AP
    Cancer Treat Rep; 1982 Jul; 66(7):1495-500. PubMed ID: 7046930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for 131I-meta-iodobenzylguanidine therapy.
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP23-6. PubMed ID: 12723562
    [No Abstract]   [Full Text] [Related]  

  • 9. Guidelines for 131I-ethiodised oil (Lipiodol) therapy.
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP20-2. PubMed ID: 12723561
    [No Abstract]   [Full Text] [Related]  

  • 10. Radiophosphorus (32P) treatment of bone marrow disorders in dogs: 11 cases (1970-1987).
    Smith M; Turrel JM
    J Am Vet Med Assoc; 1989 Jan; 194(1):98-102. PubMed ID: 2914806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32--a 15 year review.
    Balan KK; Critchley M
    Br J Radiol; 1997 Nov; 70(839):1169-73. PubMed ID: 9536909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorus-32: the forgotten radiopharmaceutical?
    Vinjamuri S; Ray S
    Nucl Med Commun; 2008 Feb; 29(2):95-7. PubMed ID: 18094629
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of different doses of 32P in the treatment of primary thrombocytosis.
    Randi ML; Fabris F; Varotto L; Peverelli P; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):950-6. PubMed ID: 2419226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D; Tefferi A
    Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Radioactive phosphorus (32P); an old, but not bad treatment in polycythemia vera].
    Michiels JJ; van Genderen PJ
    Ned Tijdschr Geneeskd; 1997 Jan; 141(3):168-9. PubMed ID: 9053768
    [No Abstract]   [Full Text] [Related]  

  • 16. Observations on polycythemia vera turning into acute or chronic granulocytic leukemia during treatment with radioactive phosphorus 32P.
    Krańik W
    Pol Med Sci Hist Bull (1973); 1975; 15(4):447-52. PubMed ID: 1063385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 18. New horizons for therapeutic nuclear medicine in 1981.
    Beierwaltes WH
    J Nucl Med; 1981 Jun; 22(6):549-54. PubMed ID: 7229726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematology problem. Myeloproliferative disorders.
    Saumur JH; Coleman ML; Larson LM
    Am J Med Technol; 1979 Jul; 45(7):634-7. PubMed ID: 573066
    [No Abstract]   [Full Text] [Related]  

  • 20. Radionuclide therapy of hematologic disorders.
    Silberstein EB
    Semin Nucl Med; 1979 Apr; 9(2):100-7. PubMed ID: 482947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.